- Otsuka and Lundbeck tout alliance benefits as they mull future CNS strategy
- Lundbeck sales refocus puts 600 EU jobs at risk
- Lundbeck's alcohol dependence drug approved in Europe
- Lundbeck issues profit warning as R&D boosted to combat slower sales
ONLY 0 DAY LEFT
|Stay close to your market. Renew online now to ensure uninterrupted access to:|
|SCRIP Intelligence's news and expert commentary|
|Market Data and Company Analysis (SCRIP 100, SCRIP Asia 100)|
|The Ask the Analyst Service...and more.|
Please remember to quote your order number and customer number.
You can also renew by calling: +44 (0)20 7017 5540.